You are here


  • ECCO 2017 webcasts - Part 1

    Welcome & Introduction" by Nicholas Thatcher

    Nicholas Thatcher introduces the symposium topic: “Debating the optimal management in advanced and metastatic lung cancer: The right treatment for the right patient at the right time”.
    Nicholas Thatcher - Welcome and Introduction at ECCO 2017 NSCLC
  • ECCO 2017 webcasts - Part 2

    'Identifying the right patient: histological and molecular profiling challenges' by Keith Kerr

    With more insights into the molecular characteristics of lung cancer cells and the evolvement of new technologies diagnosis and treatment is more targeted and equally complicated – a lecture of Keith Kerr, University of Aberdeen.
    Keith Kerr -  Identifying the right patient: histological and molecular profiling challenges at ECCO 2017 NSCLC
  • ECCO 2017 webcasts - Part 3

    "Maximizing Treatment Outcomes in Patients with Advanced Metastatic Lung Cancer" by Giorgio V Scagliotti

    Giorgio Scagliotti builds a modern-day algorithm for selecting individualized therapies in nonsquamous non-small cell lung cancer and squamous non-small cell lung cancer based on molecular biomarkers and clinical trial results. He highlights the improvements in our abilities to better target therapies but also addresses the limitations in translating clinical trial data to the clinical setting, and discusses the gaps in therapy that still remain in this patient population. Finally, he comments on the issues remaining with effectively incorporating immunotherapy strategies into the clinic.
    Giorgio V Scagliotti - Maximizing Treatment Outcomes in Patients with Advanced Metastatic Lung Cancer at ECCO 2017 NSCLC
  • ECCO 2017 webcasts - Part 4

    "The right time, the right sequence" by Nicholas Thatcher

    Using a case study in a 76-year old male with squamous non-small cell lung cancer, Dr Thatcher explores the significance of clinical trial results from a clinician’s perspective versus those of a patient. He suggests that while a 6-week increase in overall survival may be considered to be a minimal improvement by clinicians, to the patient it could mean a great deal. He also challenges the guidelines that currently define the age that is “too old” for chemotherapy, citing evidence that in people over 70 years of age chemotherapy can have substantial benefits.
    Nicholas Thatcher - The Right Time, the Right Sequence and the Right Combination for the Right Result at ECCO 2017 NSCLC
  • ECCO 2017 webcasts - Part 5

    "Medical management of advanced NSCLC" by Christian Manegold

    Three antiangiogenic agents have been incorporated into current treatment algorithms for non-small cell lung cancer (NSCLC). Dr Manegold reviews clinical trial data that supports the addition of these agents to platinum-based chemotherapy, as well as the addition to other targeted agents such as monoclonal antibodies or small tyrosine kinase inhibitors. He discusses early results from small clinical trials that combine antiangiogenic agents with immune-checkpoint inhibitors. He also explores the questions that remain for creating a treatment algorithm for combining antiangiogenic agents with immune-checkpoint inhibitors for NSCLC therapy.
    Christian Manegold - Medical management of advanced NSCLC at ECCO 2017
  • How I optimize treatment for my NSCLC patients with advanced aggressive disease


    Silvia Novello chairs this session on advanced NSCLC. The goal is to leave attendees better informed about: the reasons behind the limited treatment options, the advances towards better therapies and how to develop effective care plans using effective treatment sequencing and a multidisciplinary team.
    Silvia PILC2017
  • How I select the right treatment for the right patient: histological and molecular profiling challenges


    Fernando López-Ríos is a pathologist who in this session addresses current issues in collecting quality samples to achieve the most accurate diagnoses, and describes the current state of analytical testing for NSCLC and the benefits and limitations of the many analytical tools. He then reviews how to present pathology findings in the way that best benefits clinicians and patients.
    Fernando PILC2017
  • How I optimize treatment for my patients with advanced non-squamous NSCLC: present options and future perspectives


    Joachim Aerts reviews the ESMO clinical practice guidelines for diagnosis, treatment and follow-up of metastatic non-squamous NSCLC which were updated in 2016. He reviews the treatment algorithm for 1 st -line and 2 nd -line, and comments on promising upcoming clinical trial data. He looks at the newest clinical trial data on targeted therapies, and refers to the need to sequence these therapies in order to give patients the best care possible. He comments on the future of therapy combinations for this patient population.
    Joachim PILC2017
  • How I optimize treatment for my patients with advanced squamous NSCLC: present options and future perspectives


    Luis Paz-Ares reviews the current treatment strategies for squamous NSCLC and defines the differences between squamous and non-squamous NSCLC. He highlights the need for further research and better treatments, as even though small steps have been made in 1 st - and 2 nd -line, overall prognosis continues to be poor.
    Luis PILC2017

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Society partner

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

A few pearls from ELCC 2017

5-8 May 2017, Geneva

by Stefan Zimmermann

A high-level forum where critical issues we face as thoracic oncologists are discussed, and cutting-edge new research is presented. 

Perspectives in Lung Cancer 2017

How I optimize treatment for my NSCLC patients with advanced and aggressive disease

Now available: Webcast on demand


Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.